Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that the National Institute for Health and Care Excellence's evaluation processes complement the Medicines and Healthcare products Regulatory Agency's International Recognition Procedure.
Answered by Andrew Stephenson
The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the processes that it uses, in the development of its recommendations on new medicines. The NICE will continue aiming to publish guidance on new medicines within 90 days of the receipt of a United Kingdom marketing authorisation, and is working closely with the Department, the Medicines and Healthcare products Regulatory Agency, industry, and system partners to ensure that it is able to make timely recommendations on new medicines licensed through the International Recognition Procedure.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much and what proportion of NHS England funding is expected to go to integrated care boards in the 2023-24 financial year; how much and what proportion of NHS England funding went to integrated care boards in the 2022-23 financial year; and how much and what proportion of NHS England funding went to clinical commissioning groups in (a) 2019-20, (b) 2020-21 and (c) 2021-22 financial years.
Answered by Will Quince
The following table shows the total final allocation to integrated care boards (ICBs) and/or clinical commissioning groups (CCGs) for the financial years 2019/20 to 2022/23, plus the current annual allocation value as at month two for 2023/24. This includes all allocations to ICBs and/or CCGs, including core programme funding, services delegated to ICBs such as general practice and other primary care services, and additional allocations for specific service development and transformation programmes.
The remainder of NHS England’s allocation, not allocated to ICBs, pays mainly for other National Health Service services and costs not commissioned by ICBs. This includes specialised services, vaccinations and screening, education and training, and other centrally managed NHS costs.
| Financial year | ||||
2019/20 | 2020/21 | 2021/22 | 2022/23 | 2023/24 | |
£ million | £ million | £ million | £ million | £ million | |
CCG and/or ICB allocation | 89,730 | 101,907 | 115,007 | 119,174 | 123,880 |
Total NHS England allocation (Non-ring-fenced RDEL) | 123,377 | 149,473 | 150,614 | 158,521 | 167,313 |
| |||||
CCG/ICB allocation as % of total allocation | 73% | 68% | 76% | 75% | 74% |
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to put in place additional measures to tackle cancer treatment waiting times.
Answered by Will Quince
Reducing cancer treatment waiting times is already a priority for this Government. The Department is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care. The Government plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity.
In the 2023/24 Operational Planning Guidance, NHS England announced it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years to support delivery of the strategy and the operational priorities for cancer which includes increasing and prioritising diagnostic and treatment capacity for cancer.
Additionally, the Government recently published the Major Conditions Strategy Case for Change and Our Strategic Framework on 14 August which sets out our approach to making the choices over the next five years that will deliver the most value in facing the health challenges of today and of the decades ahead, including for cancer.
NHS England continues to actively support those trusts requiring the greatest help to cut cancer waiting lists and treatment and the Department is working with NHS England to make further improvements.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support is available specifically for people with cancer who experience long waits for treatment.
Answered by Will Quince
The Government is working with NHS England to reduce waiting times for cancer treatments and to ensure support is available for those that are wating for treatment. The Government and the National Health Service are committed to ensuring that all cancer patients get access to a Holistic Needs Assessment and Personalised Care Interventions. These will ensure care focuses on what matters most to each person, whilst empowering them to self-manage where appropriate and providing a route back into the system if they notice any worrying changes or need to seek help.
NHS England is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years to support the delivery of priorities in cancer, including working to ensure that every person receives personalised care and support from cancer diagnosis onwards.
The NHS is supporting adults with the NHS Talking Therapies which provides evidence-based mental health services for people with anxiety and depression. The pathway has been identified as a priority to support the integration of mental and physical health services for people with long-term conditions such as cancer.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps the NHS is taking to fund Baricitinib for the treatment of severe alopecia areata.
Answered by Will Quince
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended in a NICE appraisal, usually within three months of final guidance.
NICE published final draft guidance on 18 May 2023 which does not recommend baricitinib for the treatment of severe alopecia areata. An appeal has been made against NICE’s final draft guidance by Alopecia UK which will be considered by NICE’s appeal panel on 12 September 2023. NICE will issue final guidance in due course.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to Question 135 of his oral evidence to the Health and Social Care Committee on 20 June 2023, HC 1093, whether his Department plans to implement the recommendation in the Office for Health Improvement and Disparities report entitled Nicotine Vaping in England: 2022 evidence update summary, published on 29 September 2022, by requesting that the Committee on Toxicity update their review, entitled Statement on the toxicological evaluation of novel heat-not-burn tobacco products, published in December 2017.
Answered by Neil O'Brien - Shadow Minister (Education)
There are no current plans to request the Committee on Toxicity to update their review on heat-not-burn tobacco products. However, the Office for Health Improvements and Disparities will continue to monitor international evidence related to the health harms of these products.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps he has taken to help younger men with their mental health.
Answered by Maria Caulfield
We are investing at least £2.3 billion of additional funding a year by March 2024 through the NHS Long Term Plan to expand and transform mental health services in England so that two million more people, including younger men, will be able to get the mental health support they need.
This investment includes an additional £57 million in suicide prevention by March 2024. Through this, all areas of the country are seeing investment to support local suicide prevention plans and the development of suicide bereavement services.
The Government launched a public call for evidence on what can be done across Government in the longer term to support mental health, wellbeing, and suicide prevention, which closed on 7 July 2022. We received submissions from 5,273 respondents representing a broad range of stakeholders, including those working with younger men, from across England. These responses will feed into the development of mental health and suicide prevention policies we include in the Major Conditions Strategy and the Suicide Prevention Strategy.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many integrated care boards include representatives of dentists.
Answered by Neil O'Brien - Shadow Minister (Education)
The information requested is not held centrally.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the time taken to diagnosis people with bipolar disorder.
Answered by Maria Caulfield
The NHS Long Term Plan commits to investing approximately £1 billion by 2023/24 to increase access to high quality care in the community for people with severe mental illness, including bipolar disorder. Through the new models of care provided by integrated care systems, services will be based on the needs of individuals, rather than solely on diagnoses. This follows feedback received from those with severe mental illnesses, such as bipolar disorder, during the development of the community mental health framework.
Information on National Health Service expenditure on services and treatments specifically for people with bipolar disorder is not held in the format requested.
Asked by: Paul Bristow (Conservative - Peterborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of the health spend is on services and treatments for people with bipolar disorder.
Answered by Maria Caulfield
The NHS Long Term Plan commits to investing approximately £1 billion by 2023/24 to increase access to high quality care in the community for people with severe mental illness, including bipolar disorder. Through the new models of care provided by integrated care systems, services will be based on the needs of individuals, rather than solely on diagnoses. This follows feedback received from those with severe mental illnesses, such as bipolar disorder, during the development of the community mental health framework.
Information on National Health Service expenditure on services and treatments specifically for people with bipolar disorder is not held in the format requested.